Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma

Takashi Maruyama*, Yoshihiro Muragaki, Eiichi Ishikawa, Koji Tsuboi, Hiroshi Iseki, Tadao Ohno, Akira Matsumura, Yoshikazu Okada

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).

Original languageEnglish
Pages (from-to)448-455
Number of pages8
Issue number6
Publication statusPublished - 2010 Nov
Externally publishedYes


  • Autologous formalin-fixed tumor vaccine
  • Clinical trial
  • Glioblastoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Autologous formalin-fixed tumor vaccine for initially-diagnosed glioblastoma'. Together they form a unique fingerprint.

Cite this